Success Stories: EB-1A Approved for Scientist in California in the Field of Ophthalmology

 

Client’s Testimonial:

 

I appreciate your help and professionalism loads!  I will post a review on mitbbs.

 


On June 2nd, 2015, We Received Another EB1-A (Alien of Extraordinary Ability) Approval for a Scientist in the Field of Ophthalmology (Approval Notice)


General Field: Ophthalmology

Position at the Time of Case Filing: Scientist

Country of Origin: China

Service Center: Nebraska Service Center (NSC)

State of Residence at the Time of Filing: California

Approval Notice Date: June 2nd, 2015

Processing Time: 4 days (Premium Processing Requested)

 

 


Case Summary:

In this case, the client that we had the opportunity to work with was a Scientist from China in the field of Ophthalmology.  His specialized research has focused on the investigation and development of novel therapeutic and clinical strategies for treating Experimental Autoimmune Uveitis (EAU), along with the improvement of gene therapy and artificial bone formation techniques. His work had resulted in 132 peer-reviewed scientific articles and numerous presentations at national and international conferences; at the time that his case was filed, his publications had been cited at least 620 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work.  He had also reviewed 50 manuscripts for distinctive, internationally-circulated journals.  His superior level of expertise was confirmed in the following quote from an independent recommender, “[Client]’s contribution of modified chitosan as an effective gene carrier for transfection is something that cannot be overstated. It is a game-changer that revolutionizes the pharmaceutical industry and the realm of gene therapy specifically.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Ophthalmology, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in 4 days.